Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study SIR, SSc is characterized by fibrotic thickening of the skin and internal organs and widespread vascular damage [1] . The first vascular event is RP and digital ulcers (DUs) are frequently occurring in SSc evolving to fingertip necrosis, gangrene and amputation with high impact on quality of life [2] . An important pathogenic role is played by endothelin, a molecule with a potent vasoconstrictor agent which is elevated in SSc [3] . The endothelin receptor antagonists have given significant results in the therapy of pulmonary arterial hypertension (PAH), while the only randomized clinical trial in the treatment of DUs is limited to bosentan [4, 5] .
In our study, we evaluated the efficacy and tolerability of ambrisentan in the treatment of DUs in patients who failed bosentan. The study and the off-label use of this drug has been approved by the hospital ethics committee (comitato etico interaziendale A.S.O. San Giovanni Battista, A.S.O. C.T.O./C.R.F./Maria Adelaide Di Torino) and by the hospital pharmaceutical commission after submission of documentation supporting the treatment. All patients were given a detailed explanation of the study and informed consent was obtained. Six patients, aged between 40 and 68 years (mean age 53.7 AE 11.3 years), with SSc according to ACR Criteria [6], presenting DUs with an onset of between 6 and 9 months were consecutively recruited. Four of the six patients had limited ACA-positive SSc and two of them had SCL-70 antibody-positive diffuse SSc. The mean duration of SSc was 7.1 years with an average duration of onset of RP of 12.3 years. None of the six patients was suffering from PAH. These patients had been treated with ACE inhibitors, prostanoids and bosentan (at least for 6 months) suspended due to unsatisfactory results or side effects. The recruited patients continued to receive i.v. therapy with prostanoids. After 1 month of wash-out after bosentan therapy, patients were treated with ambrisentan. The recruitment period and analysis of the study were conducted between September 2011 and May 2012. Ambrisentan was administered at 5 mg/day and safety follow-up was performed every 4 weeks for 6 months. Each patient was given a diary to report at each visit as follows: date of onset and duration of RP, Raynaud's Condition Score (RCS) and number of daily attacks, visual analogue scale (VAS) for pain (110), ulcer onset and location.
At baseline and at each visit, blood samples for routine analysis and tests [e.g. pregnancy test, scleroderma HAQ disability index (HAQ-DI)] were performed. Categorical variables were compared using independent samples t-test and skewed outcome measures using Mann Whitney U-test. A P-value <0.05 was considered statistically significant.
In four patients, all ulcers healed completely, while in two patients only one DU each was still evident at the end of the treatment. At week 24, the number of RP attacks was significantly decreased (Á À3.10, P = 0.01), RP duration was decreased without reaching statistical significance (Á À14.5, P = 0.077), the RCS was instead significantly improved (Á À2.3, P = 0.03) as well as pain VAS (Á À3.5, P = 0.02). The HAQ-DI did not give meaningful results even if there was a trend for improvement. During the 24 weeks of treatment, no new ulcers were observed and a significant number of ulcers healed completely-at baseline there were 2.67 AE 0.82 and at week 24 there were 0.33 AE 0.52 (P < 0.03). Videocapillaroscopy and the evaluation of pulmonary function (FVC, DL CO and 6MWT) and heart (echocardiography, NT-proBNP and troponin) did not change during the study. No liver increase was observed during treatment with ambrisentan (Table 1) .
A prospective uncontrolled long-term treatment with bosentan showed a significant decrease in the number of DUs [7] . To date, there are only few data, limited to individual experiences, on ambrisentan in DUs treatment [8] . This is the first report on the effect of ambrisentan in a limited number of SSc patients without PAH who were previously unsuccessfully treated with bosentan. This study showed significant reduction in the total number of DUs, with no appearance of new lesions in a winter period of observation. The reduction of DUs led to a significant decrease of pain and disability. Patients who had shown increased >3 Â ULN increase in liver enzymes during treatment with bosentan did not show intolerance to the treatment with ambrisentan. The values of liver transaminases have remained consistently under 3 Â ULN and no other hepatic adverse events occurred. Our data also indicate a reduction in RP attacks, VAS pain and RCS in agreement with other studies with bosentan [9] . The data currently available in the literature on the degree of disability by HAQ-DI [10] show a trend towards improvement although not always statistically significant, as in our cases.
In conclusion, our data, although obtained in a small number of patients, suggest that ambrisentan might be useful in the treatment of DUs in SSc patients. We believe that at least for those patients who failed to improve on bosentan, ambrisentan may be an alternative treatment. Long-term studies with a wider coverage must be performed to assess the effects of ambrisentan in terms of prevention and healing of DUs and disability in patients with SSc.
Rheumatology key message
. Ambrisentan might be useful as an alternative treatment for DUs in SSc patients. A novel arthritis in vivo fluorescence optical imaging technology pushed to the limits SIR, Fluorescence optical imaging (FOI) is a novel method that is increasingly utilized for visualizing arthritides by detecting local hyperperfusion. We report on a 57-year-old man of Indian heritage, suffering from an ACR criteriapositive RA. At the first visit to our clinic the patient complained of painful and swollen finger joints of several weeks duration. Clinical examination (CE) showed signs of a highly active polyarthritis involving both wrists and multiple small finger joints, which was reflected by a DAS28 score of 6.28. Laboratory evaluation revealed an elevated ESR of 53 mm/h (029 mm/h) and elevated CRP of 23 mg/l (45.0 mg/l). In addition, the following abnormal laboratory parameters were observed: haemoglobin 12.7 g/l, RF 127 U/ml, anti-CCP 250 U/ml and anti-modified citrullinated vimentin antibodies (anti-MCV) 669 U/ml. Musculoskeletal US (MUS) demonstrated highly active polysynovitis, with a US7 score of 17 [1] . Conventional radiographic examinations revealed no erosions. After obtaining the patient's consent, a novel in vivo FOI technique was applied that uses the US Food and Drug Administration-approved fluorescence dye indocyanine green (ICG) to determine microperfusion. The FOI examination follows a standardized protocol by placing both hands on a preformed hand rest, followed by injection of an ICG bolus (0.1 mg/kg/body weight i.v.) and subsequent imaging with one image every second for a total of 6 min. Alterations of fluorophore concentration are depicted as alterations in signal intensity. As we observed highly active polysynovitis both clinically and sonographically, we expected to see similar changes in the FOI examination. However, the results did not correlate with the MUS findings or the CE (Fig. 1) . Under various experimental conditions, FOI proved to correspond to the degree of synovitis [2, 3] . In those experiments, early hyperaemia of inflamed joints could be detected by recording scattering and absorption patterns of light transmitted through inflamed finger joints. This approach has already been tested in humans [4, 5] , which led to the development of an FOI system with fixed optical geometry used in our patient (Xiralite X4; Mivenion GmbH, Berlin, Germany). So far only two larger clinical studies that examine the novel FOI method in comparison with established imaging modalities have been published [6, 7] . The study by Werner et al. 
